Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

J Natl Cancer Inst 2020 Feb 15. Epub 2020 Feb 15.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

The incidence of melanoma in the United States has been increasing over the past several decades. Prognosis largely depends on disease stage, with 5-year melanoma-specific survival ranging from as high as 99% in patients with stage I disease to less than 10% for some patients with stage IV (distant metastatic) disease. Fortunately, in the last 5-10 years, there have been remarkable treatment advances for patients with high-risk resectable melanoma, including approval of targeted and immune checkpoint blockade therapies. In addition, results of recent clinical trials have confirmed the importance of sentinel lymph node biopsy and continue to refine the approach to regional lymph node basin management. Lastly, the melanoma staging system was revised in the eighth edition AJCC Cancer Staging Manual, which was implemented on January 1, 2018. Here we discuss these changes and the clinicopathological features that confer high risk for locoregional and distant disease relapse and poor survival. Implications regarding the management of melanoma in the metastatic and adjuvant settings are discussed, as are future directions for neoadjuvant therapies.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djaa012DOI Listing
February 2020

Publication Analysis

Top Keywords

resectable melanoma
8
lymph node
8
high-risk resectable
8
patients stage
8
clinicopathological features
8
melanoma
5
blockade therapies
4
checkpoint blockade
4
immune checkpoint
4
distant disease
4
risk locoregional
4
locoregional distant
4
therapies addition
4
trials confirmed
4
confirmed sentinel
4
high risk
4
clinical trials
4
addition clinical
4
targeted immune
4
approval targeted
4

Similar Publications